Somatostatin Receptor 1 and 5 Double Knockout Mice Mimic Neurochemical Changes of Huntington's Disease Transgenic Mice

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Sep 14

PMID 21912697

Citations 14

Authors

Padmesh S Rajput

Geetanjali Kharmate

Michael Norman

Shi-He Liu

Bhagavatula R Sastry

Charles F Brunicardi

Ujendra Kumar

Affiliations

Soon will be listed here.

Abstract

Background: Selective degeneration of medium spiny neurons and preservation of medium sized aspiny interneurons in striatum has been implicated in excitotoxicity and pathophysiology of Huntington's disease (HD). However, the molecular mechanism for the selective sparing of medium sized aspiny neurons and vulnerability of projection neurons is still elusive. The pathological characteristic of HD is an extensive reduction of the striatal mass, affecting caudate putamen. Somatostatin (SST) positive neurons are selectively spared in HD and Quinolinic acid/N-methyl-D-aspartic acid induced excitotoxicity, mimic the model of HD. SST plays neuroprotective role in excitotoxicity and the biological effects of SST are mediated by five somatostatin receptor subtypes (SSTR1-5).

Methods And Findings: To delineate subtype selective biological responses we have here investigated changes in SSTR1 and 5 double knockout mice brain and compared with HD transgenic mouse model (R6/2). Our study revealed significant loss of dopamine and cAMP regulated phosphoprotein of 32 kDa (DARPP-32) and comparable changes in SST, N-methyl-D-aspartic acid receptors subtypes, calbindin and brain nitric oxide synthase expression as well as in key signaling proteins including calpain, phospho-extracellular-signal-regulated kinases1/2, synapsin-IIa, protein kinase C-α and calcineurin in SSTR1/5(-/-) and R6/2 mice. Conversely, the expression of somatostatin receptor subtypes, enkephalin and phosphatidylinositol 3-kinases were strain specific. SSTR1/5 appears to be important in regulating NMDARs, DARPP-32 and signaling molecules in similar fashion as seen in HD transgenic mice.

Conclusions: This is the first comprehensive description of disease related changes upon ablation of G- protein coupled receptor gene. Our results indicate that SST and SSTRs might play an important role in regulation of neurodegeneration and targeting this pathway can provide a novel insight in understanding the pathophysiology of Huntington's disease.

Citing Articles

Neuropeptide System Regulation of Prefrontal Cortex Circuitry: Implications for Neuropsychiatric Disorders.

Casello S, Flores R, Yarur H, Wang H, Awanyai M, Arenivar M Front Neural Circuits. 2022; 16:796443.

PMID: 35800635 PMC: 9255232. DOI: 10.3389/fncir.2022.796443.

Somatostatin and Somatostatin-Containing Interneurons-From Plasticity to Pathology.

Liguz-Lecznar M, Dobrzanski G, Kossut M Biomolecules. 2022; 12(2).

PMID: 35204812 PMC: 8869243. DOI: 10.3390/biom12020312.

Somatostatin-Mediated Regulation of Retinoic Acid-Induced Differentiation of SH-SY5Y Cells: Neurotransmitters Phenotype Characterization.

Singh S, Somvanshi R, Kumar U Biomedicines. 2022; 10(2).

PMID: 35203546 PMC: 8961784. DOI: 10.3390/biomedicines10020337.

The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders.

Song Y, Yoon J, Lee S Exp Mol Med. 2021; 53(3):328-338.

PMID: 33742131 PMC: 8080805. DOI: 10.1038/s12276-021-00580-4.

Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma.

Liu S, Yu J, Creeden J, Sutton J, Markowiak S, Sanchez R Cancer Lett. 2020; 491:97-107.

PMID: 32829010 PMC: 8766172. DOI: 10.1016/j.canlet.2020.08.002.

References

Huang Q, Zhou D, Sapp E, Aizawa H, Ge P, BIRD E . Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Neuroscience. 1995; 65(2):397-407. DOI: 10.1016/0306-4522(94)00494-p. View

Lione L, Carter R, Hunt M, Bates G, Morton A, Dunnett S . Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci. 1999; 19(23):10428-37. PMC: 6782405. View

Fan M, Raymond L . N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol. 2006; 81(5-6):272-93. DOI: 10.1016/j.pneurobio.2006.11.003. View

Ali N, Levine M . Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease. Dev Neurosci. 2006; 28(3):230-8. DOI: 10.1159/000091921. View

Ferrante R, Kowall N, Beal M, Richardson Jr E, BIRD E, Martin J . Selective sparing of a class of striatal neurons in Huntington's disease. Science. 1985; 230(4725):561-3. DOI: 10.1126/science.2931802. View

Dawbarn D, de Quidt M, Emson P . Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res. 1985; 340(2):251-60. DOI: 10.1016/0006-8993(85)90921-7. View

Hardingham G, Bading H . Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010; 11(10):682-96. PMC: 2948541. DOI: 10.1038/nrn2911. View

Nemeroff C, Youngblood W, Manberg P, Prange Jr A, Kizer J . Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science. 1983; 221(4614):972-5. DOI: 10.1126/science.6136092. View

Miyakawa T, Leiter L, Gerber D, Gainetdinov R, Sotnikova T, Zeng H . Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A. 2003; 100(15):8987-92. PMC: 166425. DOI: 10.1073/pnas.1432926100. View

10.

Bibb J, Yan Z, Svenningsson P, Snyder G, Pieribone V, Horiuchi A . Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A. 2000; 97(12):6809-14. PMC: 18747. DOI: 10.1073/pnas.120166397. View

11.

Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S . Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem. 2002; 277(22):19762-72. DOI: 10.1074/jbc.M110373200. View

12.

Baragli A, Alturaihi H, Watt H, Abdallah A, Kumar U . Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal. 2007; 19(11):2304-16. DOI: 10.1016/j.cellsig.2007.07.007. View

13.

Beal M, Ferrante R, Swartz K, Kowall N . Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci. 1991; 11(6):1649-59. PMC: 6575424. View

14.

Li S, Li X . Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 2004; 20(3):146-54. DOI: 10.1016/j.tig.2004.01.008. View

15.

Kumar U . Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus. J Comp Neurol. 2007; 504(2):185-205. DOI: 10.1002/cne.21444. View

16.

Ramirez J, Grant M, Norman M, Wang X, Moldovan S, de Mayo F . Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas. Mol Cell Endocrinol. 2004; 221(1-2):105-19. DOI: 10.1016/j.mce.2004.02.001. View

17.

Grant M, Patel R, Kumar U . The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem. 2004; 279(37):38636-43. DOI: 10.1074/jbc.M406276200. View

18.

Aronin N, Cooper P, Lorenz L, BIRD E, Sagar S, Leeman S . Somatostatin is increased in the basal ganglia in Huntington disease. Ann Neurol. 1983; 13(5):519-26. DOI: 10.1002/ana.410130508. View

19.

Rajput P, Billova S, Patel S, Kharmate G, Somvanshi R, Kumar U . Expression of somatostatin and somatostatin receptor subtypes in Apolipoprotein D (ApoD) knockout mouse brain: An immunohistochemical analysis. J Chem Neuroanat. 2009; 38(1):20-33. DOI: 10.1016/j.jchemneu.2009.05.004. View

20.

Gafni J, Hermel E, Young J, Wellington C, Hayden M, Ellerby L . Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem. 2004; 279(19):20211-20. DOI: 10.1074/jbc.M401267200. View